CALIDA TAM: Open Payments
NPI 1346003118 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,988 in 87 payments from 15 companies in 2025. Trend: 2023 $0 · 2024 $1,071 · 2025 $1,988
Food & beverage: $1,988
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 22 | $468 |
| Novo Nordisk Inc | 7 | $269 |
| AstraZeneca Pharmaceuticals LP | 10 | $250 |
| Lilly USA, LLC | 9 | $234 |
| Bayer Healthcare Pharmaceuticals Inc. | 13 | $183 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $142 |
| PFIZER INC. | 8 | $140 |
| Amgen Inc. | 5 | $108 |
| Astellas Pharma US Inc | 2 | $49 |
| Kowa Pharmaceuticals America, Inc. | 3 | $43 |
Products named: QULIPTA, JARDIANCE, Ozempic, Kerendia, VRAYLAR, NURTEC ODT, FARXIGA, KRYSTEXXA.
Industry payments across NV — which companies pay providers there.
